抗高脂血症薬の世界市場：薬物クラス別（スタチン、PCSK9阻害剤、胆汁酸封鎖剤、コレステロール吸収阻害剤、フィブリン酸誘導体、配合）...市場調査レポートについてご紹介

Chapter 1: Introduction

1.1. Report Description
1.2. Key Market Segments

1.2.1. List of Key Players Profiled In The Report

1.3. Research Methodology

1.3.1. Primary Research
1.3.2. Secondary Research
1.3.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Top Player Positioning

3.2.1. Top Investment Pockets

3.3. Key Forces Shaping Antihyperlipidemic Industry/Market
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Presence of Guidelines Recommending The Use of Statins
3.4.1.2. Surge In Healthcare Expenditure Worldwide
3.4.1.3. Rise In Prevalence of Hyperlipidemia Across The Globe

3.4.2. Restraint

3.4.2.1. Upcoming Patent Expirations of Drugs

3.4.3. Opportunity

3.4.3.1. High Growth Potential In Developing Economies

3.4.4. Impact Analyses

Chapter 4: Antihyperlipidemic Drugs Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Statins

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis By Country

4.3. Bile Acid Sequestrants

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis By Country

4.4. Cholesterol Absorption Inhibitors

4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis By Country

4.5. Fibric Acid Derivatives

4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis By Country

4.6. Pcsk9 Inhibitors

4.6.1. Key Market Trends, Growth Factors, And Opportunities
4.6.2. Market Size And Forecast, By Region
4.6.3. Market Analysis By Country

4.7. Combination

4.7.1. Key Market Trends, Growth Factors, And Opportunities
4.7.2. Market Size And Forecast, By Region
4.7.3. Market Analysis By Country

4.8. Others

4.8.1. Key Market Trends, Growth Factors, And Opportunities
4.8.2. Market Size And Forecast, By Region
4.8.3. Market Analysis By Country

Chapter 5: Antihyperlipidemic Drugs Market, By Region

5.1. Overview

5.1.1. Market Size And Forecast

5.2. North America

5.2.1. Key Market Trends And Opportunities
5.2.2. Market Analysis, By Country

5.2.2.1. U.S.

5.2.2.1.1. U.S. Market Size And Forecast, By Drug Class

5.2.2.2. Canada

5.2.2.2.1. Canada Market Size And Forecast, By Drug Class

5.2.2.3. Mexico

5.2.2.3.1. Mexico Market Size And Forecast, By Drug Class

5.2.3. North America Market Size And Forecast, By Drug Class

5.3. Europe

5.3.1. Key Market Trends And Opportunities
5.3.2. Market Analysis, By Country

5.3.2.1. Germany

5.3.2.1.1. Germany Market Size And Forecast, By Drug Class

5.3.2.2. France

5.3.2.2.1. France Market Size And Forecast, By Drug Class

5.3.2.3. Uk

5.3.2.3.1. Uk Market Size And Forecast, By Drug Class

5.3.2.4. Italy

5.3.2.4.1. Italy Market Size And Forecast, By Drug Class

5.3.2.5. Rest of Europe

5.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class

5.3.3. Europe Market Size And Forecast, By Drug Class

5.4. Asia-Pacific

5.4.1. Key Market Trends And Opportunities
5.4.2. Market Analysis, By Country

5.4.2.1. Japan

5.4.2.1.1. Japan Market Size And Forecast, By Drug Class

5.4.2.2. China

5.4.2.2.1. China Market Size And Forecast, By Drug Class

5.4.2.3. India

5.4.2.3.1. India Market Size And Forecast, By Drug Class

5.4.2.4. Rest of Asia-Pacific

5.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class

5.4.3. Asia-Pacific Market Size And Forecast, By Drug Class

5.5. Lamea

5.5.1. Key Market Trends And Opportunities
5.5.2. Market Analysis, By Country

5.5.2.1. Brazil

5.5.2.1.1. Brazil Market Size And Forecast, By Drug Class

5.5.2.2. South Africa

5.5.2.2.1. South Africa Market Size And Forecast, By Drug Class

5.5.2.3. Saudi Arabia

5.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class

5.5.2.4. Rest of Lamea

5.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class

5.5.3. Lamea Market Size And Forecast, By Drug Class

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance

6.2. Amgen Inc.

6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance
6.2.6. Key Strategic Moves And Developments

6.3. Astrazeneca Plc

6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance

6.4. Bristol-Myers Squibb Company

6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance

6.5. Daiichi Sankyo Company, Limited

6.5.1. Company Overview
6.5.2. Operating Business Segments
6.5.3. Product Portfolio
6.5.4. Business Performance

6.6. Dr. Reddy’S Laboratories Ltd

6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance

6.7. Merck & Co., Inc

6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance

6.8. Mylan N.V

6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance

6.9. Pfizer Inc.

6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance

6.10. Sanofi S.A.

6.10.1. Company Overview
6.10.2. Operating Business Segments
6.10.3. Product Portfolio
6.10.4. Business Performance
6.10.5. Key Strategic Moves And Developments